1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Pfizer Continues Positive Data Readouts For JAK Inhibitor Abrocitinib In Eczema

 
• By Joseph Haas

A second Phase III JADE study showed statistically significant skin clearance and reduced pruritus in atopic dermatitis, although safety is harder to evaluate for now. A filing planned for 2020 will include results from a cross-study comparison evaluating abrocitinib versus Dupixent.

woman in a laboratory microscope with microscope slide in hand.toned image.
Pfizer continues to build a case for its JAK1 inhibitor in atopic dermatitis

Both 100mg and 200mg doses of Pfizer Inc.’s selective JAK1 inhibitor abrocitinib demonstrated statistical significance on a pair of skin-clearance measures as well as a secondary endpoint of reducing pruritus in the Phase III JADE MONO-2 study, the company said on 27 September, confirming data for the drug in atopic dermatitis reported in May.

Pfizer’s Michael Corbo, chief development officer for inflammation and immunology, said the company hopes to file abrocitinib for US Food and Drug Administration approval in 2020. The filing will also include data from a cross-study comparison using Regeneron Pharmaceuticals Inc./Sanofi’s Dupixent (dupilumab) as an active comparator. [Editor's note: This article has been corrected to note that Pfizer is planning a cross-study comparison, not a direct head-to-head study with dupilumab

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

More from R&D

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.